Download fulltext HTML
1.
Ali-Akbar Navahi R, Chaibakhsh S, Amirpooya Alemzadeh S, Abri Aghdam K. The Adequate Number of Histopathology Cross-sections of Temporal Artery Biopsy in Establishing the Diagnosis of Giant Cell Arteritis. JOVR [Internet]. 2021Jan.20 [cited 2024May5];16(1):77–83. Available from: https://knepublishing.com/index.php/JOVR/article/view/8253

https://doi.org/10.18502/jovr.v16i1.8253

statistics

  • 737 Abstract Views
  • 368 PDF Views
  • 0 HTML Views
  • Cited by 2 articles

authors

  • Roshanak Ali-Akbar Navahi

    Roshanak Ali-Akbar Navahi

    Eye Research Center, The Five Senses Institute, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
  • Samira Chaibakhsh

    Samira Chaibakhsh

    Eye Research Center, The Five Senses Institute, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
  • Sayyed Amirpooya Alemzadeh

    Sayyed Amirpooya Alemzadeh

    Eye Research Center, The Five Senses Institute, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
  • Kaveh Abri Aghdam

    Kaveh Abri Aghdam

    Eye Research Center, The Five Senses Institute, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
    https://orcid.org/0000-0001-7568-6455

Published Date

  • Jan 20, 2021
This journal is publishing all the articles under Creative Commons Attribution License CC BY 4.0.

The Adequate Number of Histopathology Cross-sections of Temporal Artery Biopsy in Establishing the Diagnosis of Giant Cell Arteritis

Journal of Ophthalmic and Vision Research (JOVR) / January–March 2021, Volume 16, Issue 1 / Pages 77–83

Abstract

Purpose: To determine the appropriate number of histopathological cross-sections that are required for a conclusive diagnosis of giant cell arteritis (GCA).


Methods: In this cross-sectional study, the number of sections per slide for paraffin-embedded blocks for 100 randomly selected cases where GCA was suspected and those for negative temporal artery biopsies (TABs) were compared with the number of cross-sections per specimen for eight positive-TABs. All aforementioned examinations were conducted at our center from 2012 to 2016. Then, negative-TABs were retrieved and re-evaluated using light microscopy considering the histopathological findings of GCA.


Results: Ninety-five paraffin blocks were retrieved. The original mean biopsy length was 15.39 ± 7.56 mm. Comparison of the mean number of cross-sections per specimen for both the positiveand negative-TABs (9.25 ± 3.37 and 9.53 ± 2.46) showed that 9.87 ± 2.77 [95% confidence intervals (CI)] cross-sections per specimen were sufficient for a precise GCA diagnosis. There was no statistically significant difference in the mean biopsy length (P = 0.142) among the eight positive-TABs. Similarly, no significant difference was observed in the number of cross-sections per specimen (P = 0.990) for positive-TABs compared to those for the negative-TABs. After the retrieval of negative-TABs, the mean number of total pre- and post-retrieval cross-sections per specimen was 17.66 ± 4.43. Among all retrieved specimens, only one case (0.01%) showed the histopathological features of healed arteritis.


Conclusion: Positive-TABs did not reveal more histological cross-sections than the negative ones and increasing the number of cross-sections did not enhance the accuracy of TAB.

Keywords:

Giant Cell Arteritis, Histopathology Cross-sections, Temporal Artery Biopsy

References
1. Allsop C, Gallagher P. Temporal artery biopsy in giant cell arteritis: a reappraisal. Am J Surg Pathol 1981;5:317–323.

2. Mambo NC. Temporal (granulomatous) arteritis: a histopathological study of 32 cases. Histopathology 1979;3:209–221.

3. Ramstead CL, Patel AD. Giant cell arteritis in a neuroophthalmology clinic in Saskatoon, 1998-2003. Can J Ophthalmol 2007;42:295–298.

4. Evans JM, Hunder GG. Polymyalgia rheumatica and giant cell arteritis. Rheum Dis Clin North Am 2000;26:493–515.

5. Nesher G, Breuer GS. Giant cell arteritis and polymyalgia rheumatica: 2016 update. Rambam Maimonides Med J 2016;7:e0035.

6. Gajree S, Borooah S, Dhillon N, Goudie C, Smith C, Aspinall P et al. Temporal artery biopsies in south-east Scotland: a five-year review. J R Coll Physicians 2017;47:124–128.

7. Sait MR, Lepore M, Kwasnicki R, Allington J, Balasubramanian R, Somasundaram SK, et al. The 2016 revised ACR criteria for diagnosis of giant cell arteritis – our case series: can this avoid unnecessary temporal artery biopsies? Int J Surg Open 2017;9:19–23.

8. Hall S, Persellin S, Lie JT, O’Brien PC, Kurland LT, Hunder GG., et al. The therapeutic impact of temporal artery biopsy. Lancet 1983;2:1217–1220.

9. Hall S, Hunder GG. Is temporal artery biopsy prudent? Mayo Clin Proc 1984;59:793–796.

10. Nesher G. The diagnosis and classification of giant cell arteritis. J Autoimmun 2014;48–49:73–75.

11. Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990;33:1122–1128.

12. Font RL, Prabhakaran VC. Histological parameters helpful in recognising steroid-treated temporal arteritis: an analysis of 35 cases. Br J Ophthalmol 2007;91:204–209.

13. Zhou L, Luneau K, Weyand CM, Biousse V, Newman NJ, Grossniklaus HE. Clinicopathologic correlations in giant cell arteritis: a retrospective study of 107 cases. Ophthalmology 2009;116:1574–1580.

14. Stacy RC, Rizzo JF, Cestari DM. Subtleties in the histopathology of giant cell arteritis. Semin Ophthalmol 2011;26:342–348.

15. Burke A, Virmani R. Temporal artery biopsy of giant cell arteritis. Pathol Case Rev 2001;6:265–273.

16. Egge K, Midtbo A, Westby R. Arteritis temporalis. Acta Ophthalmol 1966;14:49–56.

17. Hauser WA, Ferguson RH, Holley KE, Kurland LT. Temporal arteritis in Rochester Minnesota, 1951 to 1967. Mayo Clin Proc 1971;46:567–602.

18. Roth AM, Milsow L, Keltner JL. The ultimate diagnoses of patients undergoing temporal artery biopsies. Arch Ophthalmol 1984;102:901–903.

19. Salvarani C, Macchioni P, Zizzi F, Mantovani W, Rossi F, Castri C, et al. Epidemiological and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in Northern Italy. Arthritis Rheum 1991;34:351–356.

20. Chakrabarty A, Franks AJ. Temporal artery biopsy: is there any value in examining biopsies at multiple levels? J Clin Pathol 2000;53:131–136.

21. Bhatti MT, Tabandeh H. Giant cell arteritis: diagnosis and management. Curr Opin Ophthalmol 2001;12:393–399.

22. McDonnell PJ, Moore GW, Miller NR, Hutchins GM, Green WR. Temporal arteritis. A clinicopathologic study. Ophthalmology 1986;93:518–530.

23. Lie JT. Temporal artery biopsy diagnosis of giant cell arteritis: lessons from 1109 biopsies. Anat Pathol 1996;1:69–97.

24. Bevan AT, Dunnill MS, Harrison MJ. Clinical and biopsy findings in temporal arteritis. Ann Rheum Dis 1968;2:271–277.

25. Ostberg G. Temporal arteritis in a large necropsy series. Ann Rheum Di 1971;30:224–235.

26. Poller DN, Van Wyk Q, Jeffrey MJ. The importance of skip lesions in temporal arteritis. J Clin Pathol 2000;53:137– 139.

27. Mahr A, Saba M, Kambouchner M, Polivka M, Baudrimont M, Brocheriou I, et al. Temporal artery biopsy for diagnosing giant cell arteritis: the longer, the better? Ann Rheum Dis 2006;65:826–828.

28. Cohen DN, Smith TR. Skip areas in temporal arteritis: myth versus fact. Trans Am Acad Ophthalmol Otolaryngol 1974;78:772–783.

29. Taylor-Gjevre R, Vo M, Shukla D, Resch L. Temporal artery biopsy for giant cell arteritis. J Rheumatol 2005;32:1279– 1282.

30. Sharma NS, Gal A, Benger R. Longitudinal sectioning of temporal artery biopsy specimens. Eye 2012;26:1593– 1595.

31. Stone JR, Basso C, Baandrup UT, Bruneval P, Butany J, Gallagher PJ, et al. Recommendations for processing cardiovascular surgical pathology specimens: a consensus statement from the Standards and Definitions Committee of the Society for Cardiovascular Pathology and the Association for European Cardiovascular Pathology. Cardiovasc Pathol 2012;21:2–16.

32. Klein RG, Campbell RJ, Hunder GG, Carney JA. Skip lesions in temporal arteritis. Mayo Clin Proc 1976;51:504– 510.

33. Ypsilantis E, Courtney ED, Chopra N, Karthikesalingam A, Eltayab M, Katsoulas N, et al. Importance of specimen length during temporal artery biopsy. Br J Surg 2011;98:1556–1560.

34. Miller NR. Giant cell arteritis. J Neuroophthalmol 2000;20:219–220.

35. Hayreh SS, Podhajsky PA, Raman R, Zimmerman B. Giant cell arteritis: validity and reliability of various diagnostic criteria. Am J Ophthalmol 1997;12:285–296.

36. Achkar AA, Lie JT, Hunder GG, O’Fallon WM, Gabriel SE. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med 1994;120:987–992.

37. Abri Aghdam K, Soltan Sanjari M, Manafi N, Khorramdel S, Alemzadeh SA, Ali Akbar Navahi R. Temporal artery biopsy in diagnosing giant cell arteritis: a ten-year review. J Ophthalmic Vis Res 2020;15:201–209.

38. Blockmans D, Ceuninck L, Vanderschueren S, Knockaert D, Mortelmans L, Bobbaers H. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum 2006;55:131–137.

39. Bley TA, Uhl M, Venhoff N, Thoden J, Langer M, Markl M. 3-T MRI reveals cranial and thoracic inflammatory changes in giant cell arteritis. Clin Rheumatol 2007;26:448–450.

40. Ball EL, Walsh SR, Tang TY, Gohil R, Clarke JM. Role of ultrasonography in the diagnosis of temporal arteritis. Br J Surg 2010;97:1765–1771.

41. Breuer GS, Nesher R, Nesher G. Negative temporal artery biopsies: eventual diagnoses and features of patients with biopsy-negative giant cell arteritis compared to patients without arteritis. Clin Exp Rheumatol 2008;26:1103–1106.